Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Preclinical
Sponsor : Jubilant Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Collaboration aims to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Preclinical
Sponsor : Jubilant Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : B-I09
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : University Of Notre Dame
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The team measured the ability of various inhibitors to block the RNase activity of IRE-1 in test tubes and within the cells.
Product Name : B-I09
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : B-I09
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : University Of Notre Dame
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RA 27/3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Collaboration
Wistar and Batavia Collaborate to Manufacture Rubella Vaccine
Details : Batavia Biosciences will assist Wistar Institute to streamline the clinical grade manufacture and global distribution of its rubella vaccine, RA 27/3, seed stock. Project funded by Gates Foundation.
Product Name : RA 27/3
Product Type : Vaccine
Upfront Cash : Undisclosed
April 29, 2020
Lead Product(s) : RA 27/3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Collaboration